FDA Finds Potential Carcinogen In Zantac Heartburn Drug; State Class Action Filed

(September 18, 2019, 9:04 AM EDT) -- SAN JOSE, Calif. — On the same day the Food and Drug Administration said it found the suspected carcinogen N-nitrosodimethylamine (NDMA) in the heartburn drug Zantac, four plaintiffs filed a class action lawsuit against the drug’s makers for allegedly failing to warn consumers about the presence of the contaminant (Christina Garza, et al. v. Sanofi-Aventis U.S. LLC, et al., No. 19-5772, N.D. Calif.)....

Attached Documents

Related Sections